Summary
McKesson Corporation reported strong revenue growth for the first six months of fiscal year 2024, with revenues increasing by 10% to $151.7 billion compared to the prior year period. This growth was primarily driven by the U.S. Pharmaceutical segment, which saw higher volumes and price increases, as well as growth in the Prescription Technology Solutions segment. However, net income attributable to McKesson Corporation decreased by 4% to $1.62 billion for the six-month period, resulting in diluted earnings per share of $11.95, a slight increase from $11.68 in the prior year. The decrease in net income was impacted by a significant provision for bad debts related to Rite Aid's bankruptcy and a notable discrete tax benefit in the prior year. The company continues to manage substantial opioid-related litigation liabilities, with an accrued liability of $6.6 billion as of September 30, 2023. McKesson demonstrated a commitment to returning capital to shareholders, repurchasing $1.5 billion in common stock and paying $149 million in dividends during the first six months of fiscal year 2024. The company also increased its quarterly dividend and maintained a substantial remaining authorization for share repurchases, signaling confidence in its ongoing financial health and future prospects.
Financial Highlights
52 data points| Revenue | $77.22B |
| Cost of Revenue | $74.15B |
| Gross Profit | $3.07B |
| SG&A Expenses | $2.09B |
| Operating Expenses | $2.12B |
| Operating Income | $951.00M |
| Interest Expense | $61.00M |
| Net Income | $664.00M |
| EPS (Basic) | $4.95 |
| EPS (Diluted) | $4.92 |
| Shares Outstanding (Basic) | 134.10M |
| Shares Outstanding (Diluted) | 134.80M |
Key Highlights
- 1Revenues for the six months ended September 30, 2023, increased by 10% to $151.7 billion, driven by growth in the U.S. Pharmaceutical and Prescription Technology Solutions segments.
- 2Net income attributable to McKesson Corporation decreased by 4% to $1.62 billion for the six months ended September 30, 2023, compared to $1.69 billion in the prior year.
- 3Diluted earnings per share from continuing operations increased to $11.95 for the six months ended September 30, 2023, from $11.71 in the prior year.
- 4The company recorded a $210 million provision for bad debts due to the bankruptcy of its customer, Rite Aid.
- 5McKesson's total estimated liability for opioid-related claims was $6.6 billion as of September 30, 2023.
- 6The company returned $1.7 billion to shareholders through $1.5 billion in share repurchases and $149 million in dividends in the first six months of fiscal year 2024.
- 7The Board of Directors increased the quarterly dividend to $0.62 per share and authorized an additional $6.0 billion for share repurchases.